Replies to post #23364 on Intellipharmaceutics International Inc. (IPCI)

[fabius]

My point Angelo: with one or two Andas approval before Rexista final decision and we get serious money for little IPCI.

[AngeloFoca]

I mention Glucophage because it is HUGE... the $1.2 BILLION market reflects sales of all the generics... and IF/WHEN we get approval it can immediately hit the market with Mallinckrodt.

my mistake... Glucophage's XR market is $2.4 Billion.

Assuming a 50-50 split with Mallinckrodt... every 1% of the market that IPCI/MNK capture will be $24 million... or $12 million to IPCI's bottom line... assuming 2.5% penetration IPCI's pure profit would be $30 million a year.

I believe Pristiq will be the next approval because the generic field is not yet saturated... and since there are only ~ 6 generic mfgs then if IPCI/MNK captures a mere 5% of that $843 million market that = $42 million or approx. $21 million to IPCI's bottom line.

[Tekterra]

Angelo, the reason FDA is picking and choosing which to approve first is because they are underhanded. Under normal circumstances, FDA is to approve all applications unless they have a safety reason to disapprove. They are their to serve the people. If we are to blame somebody, blame it on the prior president and his administrations. This wouldn't have happened, if FDA had all the fund it needs to provide speedy service to the public. The companies developing the drugs aren't dumb, they know all to well how much competitions are already out in the market. The FDA shouldn't even need to be concerned with the amount of competitions already out in the market and make their priority based on that.

It's sad things comes to be the way it is today. Again, hopefully we see some improvement on agency efficiency.